Equity Profile

GH

Guardant Health, Inc.

Health CareHealth Care Services$16.7B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Guardant Health Beats on EPS, Stock Up 0.01%

Metric	Actual	Expected	Surprise
EPS	$-0.45	$-0.47	+36.89%
Revenue	—	$279M	—

management commentary, guidance changes, and full analysis available with Pro.

Guardant Health Beats on EPS, Stock Up 0.01%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.45	$-0.47	+36.89%
Revenue	—	$279M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Guardant Health reported a narrower loss per share than analysts expected, which contributed to a slight increase in the stock price. However, there was no revenue reported, leaving investors with limited insights into the company's financial health. The lack of guidance and management commentary may lead to uncertainty among investors going forward.

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing advanced genomic testing services for cancer detection and treatment....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

$-0.47

Revenue

Revenue figures are crucial for assessing the company's growth and market demand for its services.

$279M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing advanced genomic testing services for cancer detection and treatment. With a market cap of $12 billion, it operates in a growing sector that leverages technology to improve patient outcomes and streamline cancer care.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

In the last quarter, Guardant Health reported an EPS of $-0.50, which was better than analysts' expectations of $-0.81, resulting in a positive surprise. However, revenue details were not disclosed, and the stock reacted negatively the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Guardant Health to report a loss of $-0.47 per share on revenues of $279 million. The company has consistently surprised on the upside in previous quarters, which could lead to a positive market reaction.

Bull Case

If Guardant Health beats EPS expectations again, it could signal strong operational efficiency and increased demand for its testing services, potentially driving the stock higher.

Bear Case

A miss on EPS or revenue could raise concerns about the company's growth trajectory and market competitiveness, leading to a negative reaction from investors.

Key Metrics to Watch

EPS

$-0.47

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$279M

Revenue figures are crucial for assessing the company's growth and market demand for its services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Guardant Health's EPS come in better than the consensus estimate of $-0.47?

A better-than-expected EPS could reinforce investor confidence and lead to a positive stock reaction.

What are the revenue figures compared to the consensus estimate of $279 million?

Revenue performance is critical for assessing growth and market demand, and any significant deviation could impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Guardant Health's ability to outperform due to its consistent track record of positive EPS surprises, indicating stronger operational resilience than analysts expect.

Supporting Evidence

The company has beaten EPS estimates in every quarter for the last two years, showcasing operational strength.

Options are pricing a 14.1% move, which is significantly higher than the historical average of 4.3%, indicating potential overreaction to expected volatility.

Key Risk

If the EPS comes in better than $-0.29, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether the company's recent positive surprises can continue amidst growing market competition.

Bull Confirmed If

An EPS of better than $-0.29 would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS worse than $-0.82 would confirm the bear case and raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.5% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

61.4%

Calls (117K)P/C Ratio: 0.17Puts (11K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$9,840.28

116 sh

1 insider

Net

$9,840.28

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant Health beats expectations, history suggests the stock could rise by about 2.1%, confirming the company's operational strength.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 4.3%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or contracts that could drive revenue growth.
2Insights into the competitive landscape and how Guardant Health plans to maintain its market position.
3Details on cost management strategies and their impact on future profitability.
4Any commentary on patient demand trends for genomic testing services.
5Updates on regulatory developments that could affect the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BMRNReported

BioMarin Pharmaceutical Inc.

RecapView

May4

PLTRReported

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing advanced genomic testing services for cancer detection and treatment....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

$-0.47

Revenue

Revenue figures are crucial for assessing the company's growth and market demand for its services.

$279M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Guardant Health beats EPS expectations again, it could signal strong operational efficiency and increased demand for its testing services, potentially driving the stock higher.

Bear Case

A miss on EPS or revenue could raise concerns about the company's growth trajectory and market competitiveness, leading to a negative reaction from investors.

Key Metrics to Watch

EPS

$-0.47

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.

Revenue

$279M

Revenue figures are crucial for assessing the company's growth and market demand for its services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Guardant Health's EPS come in better than the consensus estimate of $-0.47?

A better-than-expected EPS could reinforce investor confidence and lead to a positive stock reaction.

What are the revenue figures compared to the consensus estimate of $279 million?

Revenue performance is critical for assessing growth and market demand, and any significant deviation could impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Guardant Health's ability to outperform due to its consistent track record of positive EPS surprises, indicating stronger operational resilience than analysts expect.

Supporting Evidence

The company has beaten EPS estimates in every quarter for the last two years, showcasing operational strength.

Options are pricing a 14.1% move, which is significantly higher than the historical average of 4.3%, indicating potential overreaction to expected volatility.

Key Risk

If the EPS comes in better than $-0.29, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether the company's recent positive surprises can continue amidst growing market competition.

Bull Confirmed If

An EPS of better than $-0.29 would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS worse than $-0.82 would confirm the bear case and raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±14.1%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.5% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

61.4%

Calls (117K)P/C Ratio: 0.17Puts (11K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$9,840.28

116 sh

1 insider

Net

$9,840.28

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant Health beats expectations, history suggests the stock could rise by about 2.1%, confirming the company's operational strength.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around 4.3%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or contracts that could drive revenue growth.
2Insights into the competitive landscape and how Guardant Health plans to maintain its market position.
3Details on cost management strategies and their impact on future profitability.
4Any commentary on patient demand trends for genomic testing services.
5Updates on regulatory developments that could affect the business.